Phase I study of NPI-2358 (a novel vascular disrupting agent) in patients with solid tumors and lymphomas

被引：0
|
作者：
Mita, A. C.
Yee, L. K.
Papadopoulos, K. P.
Heath, E. I.
Romero, O.
Lloyd, G. K.
Cropp, G.
Spear, M. A.
Mita, M. M.
LoRusso, P. M.
机构：
[1] Inst Drug Dev, San Antonio, TX USA
[2] NW Med Specialties, Tacoma, WA USA
[3] Karmano Canc Inst, Detroit, MI USA
[4] Nereus Pharmaceut Inc, San Diego, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3525
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Results from phase 1 dose escalation study of the proteasome inhibitor NPI-0052 in patients with solid tumors and lymphomas
    Kurzrock, Razelle
    Hamlin, Paul
    Younes, Anas
    Hong, David
    Gordon, Michael
    Hannah, Alison
    Palladino, Michael A.
    Lloyd, G. Kenneth
    Longenecker, Angie M.
    Neuteboom, Saskia T. C.
    Cropp, Gillian F.
    Spears, Matthew A.
    Aghajanian, Carol
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3433S - 3433S
  • [42] Two phase 1 studies of MPC-6827, a novel vascular disrupting agent (VDA), in patients with advanced solid tumors and CNS metastases
    Kurzrock, R.
    Akerley, W.
    Hong, D.
    Ng, C.
    Warren, T.
    Zavitz, K.
    McCage, C.
    Laughlin, M.
    Camacho, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] A phase I and pharmacokinetic study of the vascular disrupting agent AVE8062 in combination with docetaxel, administered once every 3 weeks to patients with advanced solid tumors
    Tresca, Patricia
    Tosi, Diego
    Van Doorn, Leni
    Fontaine, Helene
    Van der Gaast, Ate
    Veyrat-Follet, Christine
    Oprea, Carina
    Dieras, Veronique
    Eskens, Ferry Alm
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [44] Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas
    Aghajanian, Carol
    Burris, Howard A., III
    Jones, Suzanne
    Spriggs, David R.
    Cohen, Marvin B.
    Peck, Ronald
    Sabbatini, Paul
    Hensley, Martee L.
    Greco, F. Anthony
    Dupont, Jakob
    O'Connor, Owen A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (09) : 1082 - 1088
  • [45] A PHASE I STUDY OF CS055, A NOVEL HISTONE DEACETYLASE INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS AND LYMPHOMAS
    Dong, M.
    Feng, F.
    Xing, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 161 - 161
  • [46] A biological and pharmacologic phase I study of NGR-TNF, a novel vascular targeting agent, in patients with refractory solid tumors (EORTC 16041).
    Van Herpen, Carla
    Fiedler, Walter
    Marreaud, Sandrine
    Van Laarhoven, Hanneke
    Peters, Marlies
    Govaerts, Anne-Sophie
    Toma, Salvatore
    Bordignon, Claudio
    Heerschap, Arend
    Punt, Kees
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3457S - 3457S
  • [47] Vascular Disrupting Agent Arsenic Trioxide Enhances Thermoradiotherapy of Solid Tumors
    Griffin, Robert J.
    Williams, Brent W.
    Koonce, Nathan A.
    Bischof, John C.
    Song, Chang W.
    Asur, Rajalakshmi
    Upreti, Meenakshi
    JOURNAL OF ONCOLOGY, 2012, 2012
  • [48] Phase I study of sapacitabine, an oral nucleoside analogue, in patients with refractory solid tumors or lymphomas
    Tolcher, A.
    Calvo, E.
    Carmona, T.
    Patnaik, A.
    Papadopoulos, K.
    Gianella-Borradori, A.
    Chiao, J.
    Cohen, R.
    EJC SUPPLEMENTS, 2006, 4 (12): : 142 - 142
  • [49] Phase I study of CYT997, a novel cytotoxic and vascular disrupting agent, given as a 24-hour intravenous infusion to patients with advanced solid tumours
    Lickliter, J.
    Smith, G.
    Burge, M.
    Coulthard, A.
    Wyld, D.
    Wilks, A.
    Vasey, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [50] Circulating endothelial cells and progenitor cells during phase I trial combining vascular disrupting agent and chemotherapy in solid tumors.
    Farace, F.
    Soria, J-C.
    Massard, C.
    Deutsch, E.
    Magne, N.
    Vassal, G.
    Bidart, J. M.
    Armand, J-P.
    ANNALS OF ONCOLOGY, 2007, 18 : 19 - 19
12345